At the beginning of the new year, a number of pharmaceutical companies such as China Resources Pharmaceutical, Dajia Wellcome and Aier Eye have successively disclosed acquisition announcements
.
Industry insiders said that this fully shows that the mergers and acquisitions of pharmaceutical companies will continue to be active
.
On January 3, Dajia Wellcome issued an updated announcement that the company intends to acquire 85.
7143% of the shares of Tianji Caotang for a purchase price of about 341 million yuan
.
After the completion of the acquisition, Dajia Wellcome will hold a total of 60 million shares of Tianji Caotang, accounting for 85.
7143%
of the total share capital of Tianji Caotang.
According to the data, Tianji Caotang is mainly engaged in the research and development, manufacturing and sales of proprietary Chinese medicines, and its main products are divided into heat and detoxification, cardiovascular and cerebrovascular and urological and other proprietary Chinese medicine series
.
For this acquisition, Dajia Wellcome said that the company belongs to the pharmaceutical circulation industry, mainly engaged in the wholesale and retail business of drugs, medical devices, etc.
, Tianji Caotang belongs to the pharmaceutical manufacturing industry, this acquisition will further expand the upstream of the industrial chain, on the basis of the company's drug wholesale and retail, specialized hospitals, has pharmaceutical production capacity, and gradually form a large-scale pharmaceutical industry business system
linked up and down.
On the same day, Fengyuan Pharmaceutical disclosed its plan to acquire assets, and the company purchased 100% of the equity of Tigermed Technology held by Tigermed Biologics by issuing shares and raised supporting funds
.
After the completion of the transaction, Tigermed will become a wholly-owned subsidiary
of the listed company.
It is understood that the acquisition began on December 19 last year, Fengyuan Pharmaceutical issued a suspension announcement, saying that the company is planning to acquire assets, and intends to acquire no less than 51% of the equity of
Anhui Tigermed Biotechnology Co.
, Ltd.
(hereinafter referred to as "Tigermed Technology" or "the target company").
At present, Anhui Tigermed Biotechnology Co.
, Ltd.
(hereinafter referred to as "Tigermed Biotechnology") holds 89.
55% of the equity
of the target company.
According to Fengyuan Pharmaceutical's asset acquisition plan, it intends to purchase 100% of the equity of Tigermed Technology held by Tigermed Biologics by issuing shares, and at the same time, the company intends to issue shares to no more than 35 specific investors to raise supporting funds
.
In addition, Aier Eye also announced on January 3 that it intends to acquire part of the equity of 14 hospitals including Shaoxing Aier and Zhoushan Aier to further improve the national regional market layout, form scale effects, and further deepen the "hierarchical chain" system
throughout the country.
Of course, in addition to domestic pharmaceutical companies, multinational companies have also made frequent moves in acquisitions in recent days
.
On January 4, Agilent announced the acquisition of life sciences company Avida Biomed, which develops high-performance targeted enrichment workflows
with unique capabilities for clinical researchers studying cancer using next-generation sequencing (NGS) methods.
The acquisition complements Agilent's market-leading SureSelect portfolio and further strengthens Agilent's strategy
to expand into high-growth clinical research and diagnostics markets.
On the same day, Canon Medical also plans to spend $300 million to open a new subsidiary in the United States, Canon Healthcare USA, aiming to strengthen the imaging business and focus sales and investment on the US market
.
It is reported that the establishment of the new company will be in January 2023, and it is expected to hire 20 employees in advance.
.
.
Industry analysts believe that the pharmaceutical industry has high technical barriers, great uncertainty in new product research and development, and strict
supervision.
With the development and growth of China's biopharmaceutical industry, it is expected that more and more leading pharmaceutical companies will continue to enhance their competitiveness and expand the industrial chain
through mergers and acquisitions in the future.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
